Could common drugs curb brain bleed aftermath?

NCT ID NCT06763055

Recruiting now Disease control Sponsor: The George Institute Source: ClinicalTrials.gov ↗

First seen Jul 08, 2026 · Last updated Jul 09, 2026 · Updated 1 time

Summary

This trial investigates whether two medications—colchicine (an anti-inflammatory) and deferoxamine (an iron chelator)—can prevent further brain injury after a hemorrhagic stroke. Up to 2,000 adults aged 18–80 with a spontaneous brain bleed will receive one of four treatments: standard care alone, colchicine for 30 days, deferoxamine for 2 days, or both drugs. The goal is to improve functional recovery and reduce disability at 6 months.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: Colchicine and Deferoxamine Mesylate
What this could lead to: If successful, this could provide a simple, widely available drug combination to reduce disability after a brain bleed.
What could go wrong: This is a large Phase 3 trial, but previous studies have not proven these drugs effective for this condition. Side effects from the drugs are possible.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for ACUTE INTRACEREBRAL HAEMORRHAGE are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

intracerebral hemorrhage stroke disorder

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

ACUTE INTRACEREBRAL HAEMORRHAGE ACUTE STROKE INTRACEREBRAL HEMORRHAGE SPONTANEOUS INTRACEREBRAL HEMORRHAGE SUPRATENTORIAL INTRACEREBRAL HAEMORRHAGE

Contacts and locations

Show contact details

Study contacts

Contact

Phone: •••-•••-•••• Email: •••••@•••••
Contact

Phone: •••-•••-•••• Email: •••••@•••••

Locations

Royal Prince Alfred Hospital
NOT_YET_RECRUITING

Sydney, New South Wales, 2050, Australia

Contact

Contact Phone: •••-•••-•••• Email: •••••@•••••
West China Hospital of Sichuan University
RECRUITING

Chengdu, Sichuan, 610041, China

Contact Phone: •••-•••-•••• Email: •••••@•••••

More trials for these conditions

Other studies related to the condition(s) this trial covers.